{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T10:35:14Z","timestamp":1781606114348,"version":"3.54.5"},"reference-count":18,"publisher":"Japanese Circulation Society","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Circ J"],"published-print":{"date-parts":[[2023,12,25]]},"DOI":"10.1253\/circj.cj-23-0349","type":"journal-article","created":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T17:12:41Z","timestamp":1700500361000},"page":"53-61","source":"Crossref","is-referenced-by-count":8,"title":["Efficacy and Safety of Sacubitril\/Valsartan in Japanese Patients With Heart Failure According to Baseline Systolic Blood Pressure\u3000\u2015 Results From a Subgroup Analysis of the PARALLEL-HF Study \u2015"],"prefix":"10.1253","volume":"88","author":[{"given":"Hiroyuki","family":"Tsutsui","sequence":"first","affiliation":[{"name":"School of Medicine and Graduate School, International University of Health and Welfare, Takagi Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin-ichi","family":"Momomura","sequence":"additional","affiliation":[{"name":"Saitama Citizens Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiko","family":"Saito","sequence":"additional","affiliation":[{"name":"Nara Prefecture Seiwa Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of General Internal Medicine 3, Kawasaki Medical School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine and Endocrinology and Metabolism, Tottori University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Sakata","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomomi","family":"Ohishi","sequence":"additional","affiliation":[{"name":"Novartis Pharma K.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Iimori","sequence":"additional","affiliation":[{"name":"Novartis Pharma K.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihito","family":"Kitamura","sequence":"additional","affiliation":[{"name":"Novartis Pharma K.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the PARALLEL-HF Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"330","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Cautela J, Tartiere JM, Cohen-Solal A, Bellemain-Appaix A, Theron A, Tibi T, et al. Management of low blood pressure in ambulatory heart failure with reduced ejection fraction patients. <i>Eur J Heart Fail<\/i> 2020; 22: 1357\u20131365.","DOI":"10.1002\/ejhf.1835"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Messerli FH, Rimoldi SF, Bangalore S. The transition from hypertension to heart failure: Contemporary update. <i>JACC Heart Fail<\/i> 2017; 5: 543\u2013551.","DOI":"10.1016\/j.jchf.2017.04.012"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Vaduganathan M, Butler J, Pitt B, Gheorghiade M. Contemporary drug development in heart failure: Call for hemodynamically neutral therapies. <i>Circ Heart Fail<\/i> 2015; 8: 826\u2013831.","DOI":"10.1161\/CIRCHEARTFAILURE.115.002271"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Veenis JF, Brunner-La Rocca HP, Linssen GCM, Van Gent MWF, Hoes AW, Brugts JJ, et al. Treatment differences in chronic heart failure patients with reduced ejection fraction according to blood pressure. <i>Circ Heart Fail<\/i> 2020; 13: e006667.","DOI":"10.1161\/CIRCHEARTFAILURE.119.006667"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Jhund PS, McMurray JJ. The neprilysin pathway in heart failure: A review and guide on the use of sacubitril\/valsartan. <i>Heart<\/i> 2016; 102: 1342\u20131347.","DOI":"10.1136\/heartjnl-2014-306775"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. <i>N Engl J Med<\/i> 2014; 371: 993\u20131004.","DOI":"10.1056\/NEJMoa1409077"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Bohm M, Young R, Jhund PS, Solomon SD, Gong J, Lefkowitz MP, et al. Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril\/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: Results from PARADIGM-HF. <i>Eur Heart J<\/i> 2017; 38: 1132\u20131143.","DOI":"10.1093\/eurheartj\/ehw570"},{"key":"8","unstructured":"8. Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: A report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. <i>J Am Coll Cardiol<\/i> 2022; 79: e263\u2013e421."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. <i>Eur Heart J<\/i> 2021; 42: 3599\u20133726.","DOI":"10.1093\/eurheartj\/ehab368"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Tsutsui H, Ide T, Ito H, Kihara Y, Kinugawa K, Kinugawa S, et al. JCS\/JHFS 2021 guideline focused update on diagnosis and treatment of acute and chronic heart failure. <i>J Card Fail<\/i> 2021; 27: 1404\u20131444.","DOI":"10.1016\/j.cardfail.2021.04.023"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Kajimoto K, Sato N, Takano T; Investigators of the Acute Decompensated Heart Failure Syndromes (ATTEND) Registry. Association of age and baseline systolic blood pressure with outcomes in patients hospitalized for acute heart failure syndromes. <i>Int J Cardiol<\/i> 2015; 191: 100\u2013106.","DOI":"10.1016\/j.ijcard.2015.04.258"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Tsutsui H, Momomura SI, Saito Y, Ito H, Yamamoto K, Sakata Y, et al. Efficacy and safety of sacubitril\/valsartan in Japanese patients with chronic heart failure and reduced ejection fraction: Results from the PARALLEL-HF study. <i>Circ J<\/i> 2021; 85: 584\u2013594.","DOI":"10.1253\/circj.CJ-20-0854"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Tsutsui H, Momomura S, Saito Y, Ito H, Yamamoto K, Ohishi T, et al. Efficacy and safety of sacubitril\/valsartan (LCZ696) in Japanese patients with chronic heart failure and reduced ejection fraction: Rationale for and design of the randomized, double-blind PARALLEL-HF study. <i>J Cardiol<\/i> 2017; 70: 225\u2013231.","DOI":"10.1016\/j.jjcc.2016.11.011"},{"key":"14","unstructured":"14. Yao YN, Zhang RC, An T, Zhang Q, Zhao XK, Zhang J. Different prognostic association of systolic blood pressure at different time points with postdischarge events in patients hospitalized for decompensated heart failure. <i>J Geriatr Cardiol<\/i> 2019; 16: 676\u2013688."},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Huang X, Liu J, Zhang L, Wang B, Bai X, Hu S, et al. Systolic blood pressure and 1-year clinical outcomes in patients hospitalized for heart failure. <i>Front Cardiovasc Med<\/i> 2022; 9: 877293.","DOI":"10.3389\/fcvm.2022.877293"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Kawase Y, Kato T, Morimoto T, Hata R, Murai R, Tada T, et al. Admission systolic blood pressure as a prognostic predictor of acute decompensated heart failure: A report from the KCHF registry. <i>PLoS One<\/i> 2021; 16: e0253999.","DOI":"10.1371\/journal.pone.0253999"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Pascual-Figal D, Bayes-Genis A, Beltran-Troncoso P, Caravaca-Perez P, Conde-Martel A, Crespo-Leiro MG, et al. Sacubitril-valsartan, clinical benefits and related mechanisms of action in heart failure with reduced ejection fraction. A review. <i>Front Cardiovasc Med<\/i> 2021; 8: 754499.","DOI":"10.3389\/fcvm.2021.754499"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Senni M, McMurray JJV, Wachter R, McIntyre HF, Anand IS, Duino V, et al. Impact of systolic blood pressure on the safety and tolerability of initiating and up-titrating sacubitril\/valsartan in patients with heart failure and reduced ejection fraction: Insights from the TITRATION study. <i>Eur J Heart Fail<\/i> 2018; 20: 491\u2013500.","DOI":"10.1002\/ejhf.1054"}],"container-title":["Circulation Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/88\/1\/88_CJ-23-0349\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,29]],"date-time":"2023-12-29T22:16:22Z","timestamp":1703888182000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/88\/1\/88_CJ-23-0349\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,25]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1253\/circj.cj-23-0349","relation":{},"ISSN":["1346-9843","1347-4820"],"issn-type":[{"value":"1346-9843","type":"print"},{"value":"1347-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,25]]},"article-number":"CJ-23-0349"}}